Beverly L. Davidson PhD

Children's Hospital of Philadelphia

Beverly L. Davidson, is Director of The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children’s Hospital of Philadelphia. She is also Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Dr. Davidson received her B.S. in Biology from the Nebraska Wesleyan University, and her Ph.D. in Biological Chemistry from the University of Michigan.

Professor Davidson's research is focused on inherited genetic diseases that cause central nervous system dysfunction, with a focus on (1) recessive, childhood onset neurodegenerative disease, in particular the lysosomal storage diseases such as the Mucopolysaccharidoses and Batten's disease; and (2) dominant genetic diseases; for example, the CAG repeat disorders (Huntington’s disease (HD) and Spinocerebellar ataxia), and (3), understanding how noncoding RNAs participate in neural development and neurodegenerative diseases processes. Her research on childhood onset neurodegenerative diseases is focused on experiments to better understand the biochemistry and cell biology of proteins deficient in these disorders, and to develop gene and small molecule based medicines for therapy. In recent work, she demonstrated that the application of recombinant viral vectors to animal models of storage disease reversed CNS deficits. To approach therapies for dominant disorders her laboratory developed and tested gene silencing and CrispR/Cas9 editing strategies for reducing expression of the disease gene in patient cells and in mice models. The Davidson lab, along with colleagues experienced in gene-based medicine delivery to humans, are advancing these promising preclinical studies to clinical trials in patients.

Recent honors include the 2009 Mathilde Solowey Award (NIH), the 2011 J.J. Armond Lecturer (AANP), the 2011 Presidential Lecture (UIowa), the 2012 Carver College of Medicine Faculty Service Award (UIowa) and the University of Iowa Innovator Award (2012), the 2014 Chair, Electorate Nominating Committee, Medical Sciences Section (AAAS), appointed to the National Advisory Council, NINDS (2014-2018); 2015 appointee to Scientific Advisory Boards of the Huntington Study Group and the Medical Research Advisory Board of the National Ataxia Foundation, and in 2017 she was elected to the American Academy of Arts and Sciences.

Dr. Davidson is a co-founder of Spark Therapeutics, Inc., and Talee Bio Inc., and serves on the Scientific Advisory Boards of Sarepta Therapeutics and Intellia Therapeutics.